Tina Patel

Have you already downloaded our new Citeline News and Insights app? Maybe you're on your way to the #GermanBiotechDays organised by BIO Deutschland e. V. or you are waiting for a plane to an important meeting and you have some free time? It's the perfect way to stay up to date with all the relevant industry news and events. I know what I'm going to do on my way to Basel for the #SwissBiotechDay #citeline #citelinecommercial #pharmanews

1

Happy Thursday all! Check out our innovative new Vγ9Vδ2 TCR Lentivirus designed to investigate Vγ9Vδ2 T cell-related cancer therapies! https://lnkd.in/grKaAVQw Background: γδ TCRs recognize antigens in a similar way to antibodies, recognizing full protein antigens and are independent of antigen binding to the MHC. γδ TCRs are cell type specific, with Vγ9Vδ2 present in T cells and ~ 5% of the T cell population in blood. Vγ9Vδ2 T cells are involved in immune responses to pathogens and long-term modulation of inflammation, and can recognize non-peptide phospho-antigens, alkylamines and synthetic amino bisphosphonates and are being studied treatment of solid tumors and hematological disorders. Vγ9Vδ2 T cells are being investigated as novel therapeutics for cancer and other pathologies, and this TCR is an excellent tool to support that drug discovery research. Reach out to me with any questions or for a quote to work with this and other T cell related tools in our CAR-T and TCR Therapy portfolios! https://lnkd.in/g-XkGyzT #drugdiscovery #cartcelltherapy #tcr #cancerresearch #immunooncology #immunotherapy #scientificresearch

17

Folks, Today is WM World Awareness Day! Please take a moment to learn more about this disease and how you can support the IWMF!! #WaldenstromaWorldAwarenessDay

23

Come join Agilent for a monthly webinar starting next month and running thru October. Hear from our technical experts and get practical knowledge on improving your chromatography. Whether you are a seasoned veteran or a beginner, our GC, and GC/MS Webinar Series will help to make you a better chromatographer so you get the reproducible results you need to make your lab more productive. You will leave with actionable tips and tricks you can apply immediately in your lab. For attending you'll receive a coupon for a 25% discount on any Agilent GC and LC Columns, Sample Prep Products and your most often used Chromatography and Spectroscopy Supplies*. Topics: May 17 - Analysis of Permanent Gases: More Challenging Than You Might Think June 20 - Take the Trouble Out of Troubleshooting: Gas Chromatography July 18 - Agilent GC/MS Solutions for Cannabis and Hemp Testing August 30 - Overwhelmed with Too Many GC Column Options? Let Us Help September 28 - Tips and Tricks: Best Practices for Column Installation and Care of GC Columns October 18 - Techniques for Avoiding Unexpected Problems in LC and GC Analysis Each webinar will start at 8:00 a.m. PT and will be approximately one hour long with a Q&A portion at the end. * Some restrictions apply

30

1 Comment

💔 #Heart failure with preserved ejection fraction (HFpEF) is a growing concern due to the ageing population and the explosion of comorbidities (#diabetes, #hypertension, sleep #apnea etc..). Epidemiological data show that the prevalence of HFpEF is increasing at a rate of 1% per year compared to heart failure with reduced ejection fraction (HFrEF) indicating that HFpEF is becoming the most common form of heart failure (source ; https://lnkd.in/d4M59wsv). 🏥 It is difficult to diagnose as there are no clear binary rules for in and out. Diagnosis depends on different pathophysiology : structural and functional activity of the heart and #natriuretic #peptide levels. ▶ There is a clear medical need for better diagnosis, management and treatment of the disease. Ultromics is a stepping stone to better healthcare but the road is still long. 💊 Let's #collaborate to develop new therapeutics. Bring your target to us at ChemBioFrance so that we can adress hand in hand this unmet medical need. #investment #drugdiscovery #diagnosis #cardiology #collaborate #research

3

Exciting news as we just released a TSLP Responsive Luciferase Reporter Ba/F3 Cell Line #82500 to support preclinical autoimmune drug discovery research: https://lnkd.in/gvKjW7R5 Summary: Thymic stromal lymphopoietin (TSLP) is a protein that functions as a type I cytokine, as an alarmin, and as a growth factor in the immune system. It is involved in type 2 immune responses, T helper type 2 responses, and in the maturation and recruitment of dendritic cells (DCs), T cells, B cells, neutrophils, mast cells, and other lymphoid cells. Its expression can be induced by infections, pro-inflammatory cytokines, proteases, and mechanical injury. TSLP is linked to allergic reactions such as asthma, atopic dermatitis, and food allergies, by inducing the expression of OX40L, CD80 and CD86, and stimulating CD4+ T cells. TSLP signals through a heterodimeric receptor of TSLP-R (CRLF2) and IL7Ra (CD127) to activate JAK2/STAT5 signaling. In 2021, the TLSP-neutralizing antibody tezepelumab was approved for the treatment of severe asthma. TSLP is an active target for investigation in ongoing clinical trials for the treatment of autoimmune disorders, and this TSLP Responsive Luciferase Reporter Ba/F3 Cell Line is a murine cell line engineered to express both TSLP-R and IL-7Ra that reports on TSLP activation via STAT5 Luciferase, making it an excellent tool for TSLP drug discovery research. Reach out to me here or by email (lmackenzie@bpsbioscience.com) with any questions or for a quote! #drugdiscovery #immunology #autoimmune #immunotherapy #scientificresearch

16

Happy Monday all! Check out this open access Frontiers in Immunology editorial by Caignard et al., discussing new insights into innate immune cell-based immunotherapies in cancer. Overview: The limited number of patients achieving an effective and durable response following T cell-centric immunotherapies indicates the urgent medical need for complementary approaches. Recent insights in innate immune cell-based cancer immunotherapies are discussed in this Research Topic, encompassing several original research manuscripts unveiling antibodies, genetic engineering and other promising strategies to enhance the anti-tumor activity of macrophages, NK and γδ T cells. Additionally, reviews within this Research Topic offer a comprehensive overview of the state-of-the-art approaches for targeting specific innate cell subtypes in cancer therapy. They also discuss emerging druggable pathways poised to advance toward clinical application in the foreseeable future, and highlight current challenges, including patient avatars as an essential tool to guide clinical decision making. #drugdiscovery #cancerresearch #immunology #cartcelltherapy #immunotherapy #immunooncology #scientificresearch

15

Up to 60% of clinical trials require biomarker info for patients to participate, but recommendations for biomarker testing to determine eligibility for clinical trials remains inconsistent. Why? We’re exploring this in an abstract and more at #ASCO24.

9

📢 Calling all flow cytometrists - Let's Talk Flow is quickly approaching! 🧪🔬 🧪 Join us for Part-II of our series on "Fluorophores: Bright is not always better." Building on last month's discussion, this session dives deeper into overcoming issues with spread in your panel. If you've encountered challenges in resolving populations due to spread, this session promises to be a game-changer. Mark your calendars and get ready to transform your approach to panel design! 🧬 🗓️Save the Date: Wednesday, June 26, 2024 at 10:00 am PDT/ 1:00 pm EDT Don't miss out on the opportunity to learn how to optimize your data and elevate your research to new heights.

2

Happy Monday all! Check out this open access Nature Genetics article by Reed et al., "A single-cell atlas enables mapping of homeostatic cellular shifts in the adult human breast." Abstract: Here we use single-cell RNA sequencing to compile a human breast cell atlas assembled from 55 donors that had undergone reduction mammoplasties or risk reduction mastectomies. From more than 800,000 cells we identified 41 cell subclusters across the epithelial, immune and stromal compartments. The contribution of these different clusters varied according to the natural history of the tissue. Age, parity and germline mutations, known to modulate the risk of developing breast cancer, affected the homeostatic cellular state of the breast in different ways. We found that immune cells from BRCA1 or BRCA2 carriers had a distinct gene expression signature indicative of potential immune exhaustion, which was validated by immunohistochemistry. This suggests that immune-escape mechanisms could manifest in non-cancerous tissues very early during tumor initiation. This atlas is a rich resource that can be used to inform novel approaches for early detection and prevention of breast cancer. #drugdiscovery #immunooncology #cancerresearch #immunotherapy #breastcancer #oncology #scientificresearch

9

5CUE.. including Understanding Breast Cancer Risk Assessment!

5

Happy Wednesday all! Hot off the presses - check out our newly released NY-ESO-1 (c259) TCR-T Cells #78990 https://lnkd.in/gVd_MkpA Background: NY-ESO-1 is an important tumorigenic marker present in malignant cells. Normally only expressed in embryonic testis, this highly immunogenic protein is re-expressed in multiple myeloma, non-small cell lung carcinoma (NSCLC), breast and ovarian cancer, making it a promising candidate antigen for cancer immunotherapy. Several NY-ESO-1-directed therapies are being developed including cancer vaccines, anti-NY-ESO-1 adoptive cell therapy, and NY-ESO-1-specific TCR-T cell therapy in combination with checkpoint inhibitors, and thus the NY-ESO-1 (c259) TCR-T Cells are an excellent tool for related cancer drug discovery research. Please reach out to me with any questions or for a quote! #drugdiscovery #cartcelltherapy #adoptivecelltherapy #cancerresearch #immunooncology #immunotherapy #scientificresearch

20

Happy Tuesday all! Hot off the presses is our new ADAR1 Activity TWO-Luciferase Reporter HEK293 Cell Line https://lnkd.in/gtu4gSNs Background: Adenosine Deaminase Acting on RNA (ADAR) enzymes perform adenosine to inosine base editing in RNA, especially targeting adenosines located within a specific double-stranded stem-loop motif (Figure 1). In healthy cells, ADAR1 activate a pro-inflammatory response through downstream dsRNA sensors. Loss-of-function mutations in ADAR1 result in aberrant activation of the dsRNA sensors and are involved in autoimmune disorders. ADAR1 dysfunction also impacts cancer cell growth, proliferation, and response to immunotherapy as ADAR1 expression is increased in many tumor types and ADAR1 KO has been shown to improve the response to immunotherapies such PD-1/PD-L1 blockade. The ability of ADAR1 activity to circumvent tumor resistance makes it an attractive target for therapeutic drug discovery, and this dual reporter cell line is an ideal tool to support that research. Please reach out to me for further information or a quote for this unique and innovative cell line to support your ADAR1 research!👩‍🔬 #drugdiscovery #cancerresearch #immunooncology #rnaediting #immunotherapy #icb #scientificresearch

9

Learn more from our Eureka Blog about innovative research being done to develop better in vitro techniques for studying so-called mechanical diseases, like hypertension or arrhythmias. https://okt.to/6Hhag8

1

Happy Friday all! Hot off the presses - we just released a TSLP Responsive Luciferase Reporter Ba/F3 Cell Line #82500 to support preclinical autoimmune drug discovery research: https://lnkd.in/gvKjW7R5 Summary: Thymic stromal lymphopoietin (TSLP) is a protein that functions as a type I cytokine, as an alarmin, and as a growth factor in the immune system. It is involved in type 2 immune responses, T helper type 2 responses, and in the maturation and recruitment of dendritic cells (DCs), T cells, B cells, neutrophils, mast cells, and other lymphoid cells. Its expression can be induced by infections, pro-inflammatory cytokines, proteases, and mechanical injury. TSLP is linked to allergic reactions such as asthma, atopic dermatitis, and food allergies, by inducing the expression of OX40L, CD80 and CD86, and stimulating CD4+ T cells. TSLP signals through a heterodimeric receptor of TSLP-R (CRLF2) and IL7Ra (CD127) to activate JAK2/STAT5 signaling. In 2021, the TLSP-neutralizing antibody tezepelumab was approved for the treatment of severe asthma. TSLP is an active target for investigation in ongoing clinical trials for the treatment of autoimmune disorders, and this TSLP Responsive Luciferase Reporter Ba/F3 Cell Line is a murine cell line engineered to express both TSLP-R and IL-7Ra that reports on TSLP activation via STAT5 Luciferase, making it an excellent tool for TSLP drug discovery research. Reach out to me here or by email (mconlon@bpsbioscience.com) with any questions or for a quote! #drugdiscovery #immunology #autoimmune #immunotherapy #scientificresearch

18

I recently came across an incredibly interesting article highlighting a novel application for NK Cell Therapy to treat Alzheimer's using NKGen Biotech, Inc. SNK01 platform. Preliminary data indicate remediation of some of the most debilitating symptoms associated with this disease, likely driven by NK cells' ability to "remove protein aggregates in the brain, while at the same time, reducing neuroinflammation". This is also a testament to the unbound potential cell therapies as we continue to explore and shift the paradigm of what is possible. It will be exciting to see how these data evolve as they progress through clinical trials in the US and Canada. https://lnkd.in/esq7v7WZ #celltherapy #alzheimers #NKcell

27

With the #FDAclearance of #IndicaLabs’ HALO AP Dx enterprise #digitalpathology platform, now’s a great time to learn more about the platform and its benefits + features. Interested? Then check out this upcoming webinar. #HALOapdx

7